Tafluprost is well tolerated in OHT eyes

Article

Preservative-free tafluprost is well tolerated in eyes with glaucoma or ovular hypertension (OHT).

Preservative-free tafluprost is well tolerated in eyes with glaucoma or ovular hypertension (OHT), reveals an investigation in the British Journal of Ophthalmology.

Dr Elena Milla and her team, Glaucoma and Genetics Unit, Institut Comtal d'Oftalmologia, Barcelona, Spain, conducted a prospective non-interventional, multicentre, observational study on 134 patients. Follow-ups were completed at baseline and one and three months post-treatment.

Five ocular surface symptoms were evaluated as absent, mild, moderate and severe. Tear break-up time, keratitis, conjunctival hyperaemia, blepharitis, Schirmer test and tear meniscus were all assessed in each patient.

A significant improvement in all symptoms was seen in 53% of patients with OHT. This included stinging/burning/irritation, itching, foreign body sensation, tearing and dryness sensation three months after treatment.

All signs except the Schirmer test results improved in the OHT patients. In the glaucomatous eyes the keratitis, hyperaemia and tear meniscus improved at one and three months post-treatment.

Preservative-free tafluprost is a well-tolerated hypotensive agent that can be used to treat naïve eyes and eyes with ocular surface problems.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.